News from proteonomix, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 01, 2013, 13:01 ET

Proteonomix Settles Litigation

 Proteonomix, Inc. (OTC: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...

Jan 14, 2013, 09:45 ET

Proteonomix Announces Extension Of Deadline

 Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the...

Jan 08, 2013, 09:42 ET

Proteonomix Announces Restructuring

Proteonomix, Inc. (the "Company") (SYMBOL: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of...

Jan 08, 2013, 09:40 ET

Proteonomix Updates Status Of UMK-121 Testing

Proteonomix, Inc. (the "Company")(Symbol PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of...

Nov 20, 2012, 09:00 ET

Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells...

Oct 26, 2012, 09:07 ET

Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...

Oct 23, 2012, 09:47 ET

Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on ClinicalTrials.gov

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...

Oct 04, 2012, 09:00 ET

Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease

 PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their...

Mar 06, 2012, 10:44 ET

Proteonomix Announces a Private Placement of $3.8 Million

 Proteonomix, Inc. (OTC/BB: PROT) announced today that it has entered into definitive agreements with certain institutional investors,...